• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Clifton R. Laduane

    2/2/24 8:11:48 PM ET
    $KMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KMPH alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Clifton R. LaDuane

    (Last) (First) (Middle)
    C/O ZEVRA THERAPEUTICS, INC.
    1180 CELEBRATION BOULEVARD, SUITE 103

    (Street)
    CELEBRATION FL 34747

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    ZEVRA THERAPEUTICS, INC. [ ZVRA ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    CFO, Secretary & Treasurer
    3. Date of Earliest Transaction (Month/Day/Year)
    01/31/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Restricted Stock Unit (1) 01/31/2024 A 130,000 (2) (2) Common Stock 130,000 $0 130,000 D
    Explanation of Responses:
    1. Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Grant to the Reporting Person of restricted stock units ("RSU").
    2. The restricted stock units will vest and settle as to one third of the restricted stock units on January 31, 2025, and the remaining two thirds of the restricted stock units will vest and settle in equal annual installment thereafter, subject in each case to the Reporting person's ongoing employment.
    /s/ R. LaDuane Clifton 02/02/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $KMPH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KMPH

    DatePrice TargetRatingAnalyst
    11/17/2022$20.00Overweight
    Cantor Fitzgerald
    9/15/2022$20.00Buy
    Canaccord Genuity
    1/31/2022$10.00 → $11.00Neutral → Buy
    HC Wainwright & Co.
    More analyst ratings

    $KMPH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by KemPharm Inc.

      SC 13G - ZEVRA THERAPEUTICS, INC. (0001434647) (Subject)

      2/14/24 4:51:40 PM ET
      $KMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by KemPharm Inc.

      SC 13G - ZEVRA THERAPEUTICS, INC. (0001434647) (Subject)

      1/29/24 5:25:49 PM ET
      $KMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by KemPharm Inc.

      SC 13G - KEMPHARM, INC (0001434647) (Subject)

      7/8/22 4:57:01 PM ET
      $KMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KMPH
    SEC Filings

    See more
    • SEC Form S-3 filed by KemPharm Inc.

      S-3 - ZEVRA THERAPEUTICS, INC. (0001434647) (Filer)

      2/2/24 9:39:30 PM ET
      $KMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • KemPharm Inc. filed SEC Form 8-K: Leadership Update

      8-K - ZEVRA THERAPEUTICS, INC. (0001434647) (Filer)

      1/23/24 7:37:15 AM ET
      $KMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • KemPharm Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - ZEVRA THERAPEUTICS, INC. (0001434647) (Filer)

      1/8/24 8:03:19 AM ET
      $KMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KMPH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on KemPharm with a new price target

      Cantor Fitzgerald initiated coverage of KemPharm with a rating of Overweight and set a new price target of $20.00

      11/17/22 7:28:54 AM ET
      $KMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Canaccord Genuity initiated coverage on KemPharm with a new price target

      Canaccord Genuity initiated coverage of KemPharm with a rating of Buy and set a new price target of $20.00

      9/15/22 7:21:45 AM ET
      $KMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • KemPharm upgraded by HC Wainwright & Co. with a new price target

      HC Wainwright & Co. upgraded KemPharm from Neutral to Buy and set a new price target of $11.00 from $10.00 previously

      1/31/22 7:18:55 AM ET
      $KMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KMPH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Schafer Joshua

      4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)

      2/2/24 9:22:49 PM ET
      $KMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Sangiovanni Timothy J.

      4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)

      2/2/24 8:17:46 PM ET
      $KMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Mickle Christal M M

      4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)

      2/2/24 8:14:52 PM ET
      $KMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KMPH
    Leadership Updates

    Live Leadership Updates

    See more
    • KemPharm Announces Board and Leadership Changes to Support its Transformation into a Leading Rare Disease Company

      Matthew R. Plooster named Chairman of the Board of DirectorsRichard W. Pascoe appointed Chief Executive OfficerTravis C. Mickle, Ph.D. transitions to PresidentJoshua Schafer appointed Chief Commercial Officer and Executive Vice President of Business Development CELEBRATION, Fla., Jan. 09, 2023 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH) (KemPharm, or the Company), a rare disease therapeutics company focused on the development of treatments for rare central nervous system (CNS), neurodegenerative diseases, lysosomal storage disorders and related treatment areas, today announced changes to its Board of Directors (Board) and executive leadership team as part of the Company's ongoing b

      1/9/23 6:30:00 AM ET
      $KMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • KemPharm Announces Appointment of Christopher Posner as New Independent Director

      24-year global pharmaceutical executive and current president and CEO of Cara Therapeutics joins KemPharm's Board of Directors CELEBRATION, Fla., Nov. 29, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH) (KemPharm, or the Company), a biotechnology company focused on the discovery, development and commercialization of novel treatments for rare central nervous system (CNS) and neurodegenerative diseases, lysosomal storage disorders and related treatment areas, today announced the appointment of Christopher Posner to serve on the Company's Board of Directors. Mr. Posner is currently the president and CEO of Cara Therapeutics (NASDAQ:CARA), a commercial-stage biopharmaceutical company.

      11/29/22 7:30:00 AM ET
      $CARA
      $KMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • KemPharm Appoints Nichol Ochsner as Vice President, Investor Relations and Corporate Communications

      CELEBRATION, Fla., Aug. 09, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH) (KemPharm, or the Company), a specialty pharmaceutical company focused on the discovery, development and commercialization of novel treatments for rare central nervous system (CNS), neurodegenerative and lysosomal storage diseases, today announced the appointment of Nichol Ochsner to the role of Vice President, Investor Relations and Corporate Communications. In this newly created position, Ms. Ochsner will be responsible for driving external awareness of KemPharm's value proposition, including ongoing relations with the Company's shareholders, covering analysts and prospective investors. "We are very plea

      8/9/22 7:30:00 AM ET
      $KMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KMPH
    Financials

    Live finance-specific insights

    See more
    • Zevra Therapeutics to Report Fourth Quarter and Full-Year 2022 Results

      CELEBRATION, Fla., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:KMPH) (Zevra, or the Company, formerly KemPharm, Inc.), a rare disease therapeutics company, has announced that the Company will host a conference call and live audio webcast on Tuesday, March 7, 2023, at 8:30 a.m. ET, to discuss its corporate and financial results for the fourth quarter and full-year 2022. The audio webcast with a slide presentation will be accessible via the Investor Relations section of the Company's website, http://investors.zevra.com/. An archive of the webcast and presentation will be available for 90 days beginning at approximately 9:30 a.m. ET, on March 7, 2023. Additionally, in

      2/27/23 7:30:00 AM ET
      $KMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • KemPharm Reports Third Quarter 2022 Results

      Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today, November 9, 2022, at 5:00 p.m. ET Significant activities underway for preparation of the arimoclomol NDA resubmissionAdvancing key activities to initiate a Phase 2 clinical trial of KP1077 in IH by year-end 2022Total cash (cash, cash equivalents and long-term investments) of $107.4M as of Sep 30, 2022; based on current operating forecast, cash runway extends into 2026 CELEBRATION, Fla., Nov. 09, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH) (KemPharm, or the Company), a biotechnology company focused on the discovery, development and commercialization of novel treatments for rare central ne

      11/9/22 4:05:00 PM ET
      $KMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • KemPharm to Report Third Quarter 2022 Financial Results

      CELEBRATION, Fla., Nov. 01, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH) (KemPharm, or the Company), a biotechnology company focused on the discovery, development and commercialization of novel treatments for rare diseases, today announced that the Company will host a conference call and live audio webcast on Wednesday, November 9, 2022, at 5:00 p.m. ET, to discuss its corporate and financial results for the third quarter 2022. The audio webcast with slide presentation will be accessible via the Investor Relations section of the Company's website, http://investors.kempharm.com/. An archive of the webcast and presentation will be available for 90 days beginning at approximately 6:

      11/1/22 7:30:00 AM ET
      $KMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KMPH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Zevra Therapeutics Begins Trading as ZVRA

      Company's common stock will begin trading on the Nasdaq Global Select Market under the new ticker symbol "ZVRA" starting today, March 1, 2023 New Company name, Zevra, is Greek for zebra, the internationally recognized symbol for the rare disease community CELEBRATION, Fla., March 01, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics (NASDAQ:ZVRA) ("Zevra" or the "Company" and formerly KemPharm, Inc.), a rare disease therapeutics company, announced today that it will begin trading under the new ticker symbol "ZVRA" on the Nasdaq Global Select Market at market open today, March 1, 2023. The Company's new corporate name, along with the corresponding ticker symbol, embody Zevra's unwa

      3/1/23 7:43:50 AM ET
      $KMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zevra Therapeutics Reiterates Commitment to Rare Disease Community as New Corporate Council Member of the National Organization for Rare Disorders (NORD)

      CELEBRATION, Fla., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:KMPH) ("Zevra" or the "Company" and formerly KemPharm, Inc.), a rare disease therapeutics company, today announced that it has become a Corporate Council member of the National Organization for Rare Disorders (NORD) and reiterated its commitment to the rare disease community by celebrating Rare Disease Day 2023. A rare disease is a condition that impacts fewer than 200,000 people in the United States, with over 7,000 known rare diseases nationally affecting nearly 1 in 10 people. NORD is dedicated to promoting research and access to therapies for the more than 300 million people worldwide with rare disea

      2/28/23 8:00:00 AM ET
      $KMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zevra Therapeutics, a Rare Disease Therapeutics Company, Files Preliminary Proxy

      CELEBRATION, Fla., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:KMPH) ("Zevra" or the "Company" and formerly known as KemPharm, Inc.), today announced it has filed its preliminary proxy statement with the U.S. Securities and Exchange Commission (the "SEC") in connection with the Company's 2023 Annual Meeting of Stockholders ("Annual Meeting"), which is scheduled to take place on April 25, 2023. Stockholders do not need to take any action with respect to the 2023 Annual Meeting at this time. In its preliminary proxy statement, Zevra announced that the Board has nominated three directors for re-election at the Company's Annual Meeting — Richard W. Pascoe, David S. Tier

      2/27/23 4:30:03 PM ET
      $KMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care